moawnect

Property	Value
?:abstract	Background Sigh is a cyclic brief recruitment manoeuvre: previous physiological studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity and increase release of surfactant. Research Question Is the clinical application of sigh during pressure support ventilation (PSV) feasible? Study Design and Methods We conducted a multi-center non-inferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or acute respiratory distress syndrome undergoing PSV. Patients were randomized to the No Sigh group and treated by PSV alone, or to the Sigh group, treated by PSV plus sigh (increase of airway pressure to 30 cmH2Ofor 3 seconds once per minute) until day 28 or death or successful spontaneous breathing trial. The primary endpoint of the study was feasibility, assessed as non-inferiority (5% tolerance) in the proportion of patients failing assisted ventilation. Secondary outcomes included safety, physiological parameters in the first week from randomization, 28-day mortality and ventilator-free days. Results Two-hundred fifty-eight patients (31% women; median age 65 [54-75] years) were enrolled. In the Sigh group, 23% of patients failed to remain on assisted ventilation vs. 30% in the No Sigh group (absolute difference -7%, 95%CI -18% to 4%; p=0.015 for non-inferiority). Adverse events occurred in 12% vs. 13% in Sigh vs. No Sigh (p=0.852). Oxygenation was improved while tidal volume, respiratory rate and corrected minute ventilation were lower over the first 7 days from randomization in Sigh vs. No Sigh. There was no significant difference in terms of mortality (16% vs. 21%, p=0.342) and ventilator-free days (22 [7-26] vs. 22 [3-25] days, p=0.300) for Sigh vs. No Sigh. Interpretation Among hypoxemic intubated ICU patients, application of sigh was feasible and without increased risk.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/moawnect_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/moawnect_hasAnnotation_C0425481> <https://research.tib.eu/covid-19/entity/moawnect_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/moawnect_hasAnnotation_C1417647>
?:creator	<https://research.tib.eu/covid-19/entity/Mauri%2C_Tommaso%3B_Foti%2C_Giuseppe%3B_Fornari%2C_Carla%3B_Grasselli%2C_Giacomo%3B_Pinciroli%2C_Riccardo%3B_Lovisari%2C_Federica%3B_Tubiolo%2C_Daniela%3B_Volta%2C_Carlo_Alberto%3B_Spadaro%2C_Savino%3B_Rona%2C_Roberto%3B_Rondelli%2C_Egle%3B_Navalesi%2C_Paolo%3B_Garofalo%2C_Eugenio%3B_Knafelj%2C_Rihard%3B_Gorjup%2C_Vojka%3B_Colombo%2C_Riccardo%3B_Cortegiani%2C_Andrea%3B_Zhou%2C_Jian-Xin%3B_D%E2%80%99Andrea%2C_Rocco%3B_Calamai%2C_Italo%3B_Gonz%C3%A1lez%2C_%C3%81nxela_Vidal%3B_Roca%2C_Oriol%3B_Grieco%2C_Domenico_Luca%3B_Jovaisa%2C_Tomas%3B_Bampalis%2C_Dimitrios%3B_Becher%2C_Tobias%3B_Battaglini%2C_Denise%3B_Ge%2C_Huiqing%3B_Luz%2C_Mariana%3B_Constantin%2C_Jean-Michel%3B_Ranieri%2C_Marco%3B_Guerin%2C_Claude%3B_Mancebo%2C_Jordi%3B_Pelosi%2C_Paolo%3B_Fumagalli%2C_Roberto%3B_Brochard%2C_Laurent%3B_Pesenti%2C_Antonio>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.chest.2020.10.079>
?:doi	10.1016/j.chest.2020.10.079
?:journal	Chest
?:license	els-covid
?:pdf_json_files	document_parses/pdf_json/05999a5162355c32294da311c817cc17462f21e7.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7664474>
?:pmid	<https://research.tib.eu/covid-19/entity/33197403.0>
?:pmid	33197403.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/05999a5162355c32294da311c817cc17462f21e7>
?:source	Elsevier; Medline; PMC
?:title	Sigh in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: the PROTECTION pilot randomized clinical trial.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-13

Property

Value

?:abstract

Background Sigh is a cyclic brief recruitment manoeuvre: previous physiological studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity and increase release of surfactant. Research Question Is the clinical application of sigh during pressure support ventilation (PSV) feasible? Study Design and Methods We conducted a multi-center non-inferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or acute respiratory distress syndrome undergoing PSV. Patients were randomized to the No Sigh group and treated by PSV alone, or to the Sigh group, treated by PSV plus sigh (increase of airway pressure to 30 cmH2Ofor 3 seconds once per minute) until day 28 or death or successful spontaneous breathing trial. The primary endpoint of the study was feasibility, assessed as non-inferiority (5% tolerance) in the proportion of patients failing assisted ventilation. Secondary outcomes included safety, physiological parameters in the first week from randomization, 28-day mortality and ventilator-free days. Results Two-hundred fifty-eight patients (31% women; median age 65 [54-75] years) were enrolled. In the Sigh group, 23% of patients failed to remain on assisted ventilation vs. 30% in the No Sigh group (absolute difference -7%, 95%CI -18% to 4%; p=0.015 for non-inferiority). Adverse events occurred in 12% vs. 13% in Sigh vs. No Sigh (p=0.852). Oxygenation was improved while tidal volume, respiratory rate and corrected minute ventilation were lower over the first 7 days from randomization in Sigh vs. No Sigh. There was no significant difference in terms of mortality (16% vs. 21%, p=0.342) and ventilator-free days (22 [7-26] vs. 22 [3-25] days, p=0.300) for Sigh vs. No Sigh. Interpretation Among hypoxemic intubated ICU patients, application of sigh was feasible and without increased risk.

is ?:annotates of